Intrapulmonary recombinant factor VIIa for diffuse alveolar hemorrhage in children

Area of Science:

• Pediatric Hematology
• Pulmonology
• Critical Care Medicine

Background:

• Diffuse alveolar hemorrhage (DAH) is a severe pulmonary complication in children with hematologic malignancies or autoimmune disorders.
• Current treatments for DAH have limited efficacy and significant complications.
• Data on intrapulmonary recombinant activated factor VII (rFVIIa) for pediatric DAH are scarce.

Purpose of the Study:

• To review institutional experience with intrapulmonary rFVIIa for treating DAH in pediatric patients.
• To evaluate the safety and efficacy of this treatment modality in a pediatric cohort.

Main Methods:

• Retrospective review of 6 pediatric patients with bronchoscopically confirmed DAH treated between 2011 and 2013.
• Treatment involved intrapulmonary rFVIIa combined with methylprednisolone, fresh-frozen plasma, and platelet support.
• Patients had diagnoses including acute myeloid leukemia, myelodysplastic syndrome, hemophagocytic lymphohistiocytosis, T-cell lymphoblastic lymphoma, and idiopathic pulmonary hemosiderosis.

Main Results:

• All 6 patients achieved complete and sustained hemostasis without adverse events.
• Significant improvement in oxygenation (PaO2/FiO2 ratio) and rapid clinical recovery were observed.
• Four out of six patients experienced long-term survival and were successfully weaned from ventilators.

Conclusions:

• Intrapulmonary rFVIIa appears to be an effective and safe treatment for pediatric DAH.
• The treatment facilitated rapid clinical improvement and enhanced survival rates in this cohort.
• Further clinical studies are warranted to confirm these findings and establish optimal protocols.